Cancer research identifies osteopontin protein as new treatment target

Researchers at the National Cancer Research Institute (CNIO) have identified the protein osteopontin as a potential new target for improving breast cancer treatments. In studies involving mice, the team found that tumor cells produce osteopontin in response to hypoxia (lack of oxygen). This protein can reprogram immune cells to protect the tumor rather than attack it, contributing to resistance against antiangiogenic drugs and immunotherapy.

Separately, the American Association for Cancer Research (AACR) released its 2026 Annual Progress Report, highlighting both scientific advancements and growing challenges. While the FDA approved eleven new cancer treatments between July 2025 and June 2026—including molecularly targeted therapies and advancements in AI-driven diagnostics—the report warns of a rising global burden. In the United States alone, cancer is projected to claim more than one life per minute this year.